samedan logo
 
 
spacer
home > ict > spring 2017 > needle in a haystack
PUBLICATIONS
International Clinical Trials

Needle in a Haystack

If there is one hot zone in drug development, it is the area of rare diseases. Formerly the province of small biotechnology companies and pharmaceutical startups, this area is now attracting the attention of increasingly bigger players, as most recently exemplified by Shire’s establishment of a separate rare disease innovation hub in Cambridge, Massachusetts, US. As we have moved beyond the blockbuster era, and with the declining productivity of Big Pharma pipelines, many larger firms are looking to rare diseases as a potential alternate revenue stream – hence the increased pace of partnering and acquisition activity, as well as efforts to expand ‘organically’ into the field.

Despite the rush of entrants into the category, conducting clinical trials in this area remains a complex proposition. Much of the difficulty is derived from the fact that many rare diseases are not as well understood as more common ailments like diabetes and hypertension. The relatively small patient populations often do not easily lend themselves to defining efficacy endpoints, inclusion and exclusion criteria or other study design elements. Such a lack of clarity makes it especially difficult to devise a protocol that will meet the FDA’s scrutiny, and could even discourage people from participating.

Incentives and Challenges

Nevertheless, pharmaceutical developers have numerous motivations for conducting these studies, including Prescription Drug User Fee Act waivers, tax credits and extended exclusivity for orphan treatments; these can give companies extra time to recoup trial-associated costs. That said, many start small – initially focusing on indications with small patient populations, which may be a springboard to expanded indications or, if they are lucky, off-label usage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Scott Treiber, PhD, MBA, is Executive Vice President of Biopharmaceutical Development at Chiltern and oversees all aspects of biopharmaceutical development including Phase 1-4 trials across a wide range of therapeutic areas. Before joining Chiltern, he held Vice President positions at Theorem, inVentiv Health, Hospira and PharmaNet. Scott is on the board of the Center for Healthcare Innovation.
spacer
Scot Treiber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AptarGroup, Inc. wins the Excellence in Pharma

AptarGroup, Inc., a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets, announces that it was awarded the inaugural Excellence in Pharma: Sustainability Initiative of the Year at CPhI Worldwide 2017. The award was presented as part of the CPhI Pharma Awards Gala, which took place Tuesday, October 24 at the Intercontinental Hotel in Frankfurt, Germany.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement